Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study.
Regional glucose metabolic rate constants and blood-to-brain transport of rubidium were estimated using positron emission tomography in an adolescent patient with a brain tumor, before and after chemotherapy with intravenous high-dose methotrexate. Widespread depression of cerebral glucose metabolism was apparent 24 hours after drug administration, which may reflect reduced glucose phosphorylation, and the influx rate constant for 82Rb was increased, indicating a drug-induced alteration in blood-brain barrier function. Associated changes in neuropsychological performance, electroencephalogram, and plasma amino acid concentration were identified in the absence of evidence of systemic methotrexate toxicity, suggesting primary methotrexate neurotoxicity.
D000208:Acute Disease; D000293:Adolescent; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001921:Brain / Q000378:metabolism*; D001927:Brain Diseases / Q000139:chemically induced*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D011868:Radioisotopes; D012413:Rubidium; D014055:Tomography, Emission-Computed
D011868:Radioisotopes; D005947:Glucose; D012413:Rubidium; D008727:Methotrexate